Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

New directions of pharmacotherapy of immune-inflammatory rheumatic diseases

Насонов Е. Л.
Терапевтический архив
Т. 91, Вып. 8, С. 98-107
Опубликовано: 2019
Тип ресурса: Статья

DOI:10.26442/00403660.2019.08.000406

Аннотация:
Deciphering immunopathogenesis, expanding the scope of diagnostics and developing new methods for treating human autoimmune diseases are among the priority areas of XXI century medicine. Particularly widely autoimmune pathology is presented in immunoinflammatory rheumatic diseases (IIRD), such as rheumatoid arthritis, systemic lupus erythematosus, systemic scleroderma, systemic vasculitis associated with the synthesis of antineutrophilic cytoplasmic antibodies, Sjogren's syndrome, idiopathic inflammatory myopathies and other other types of others. Deciphering the pathogenesis mechanisms of IIRD created the prerequisites for improving pharmacotherapy, which in the future should lead to a dramatic improvement in the prognosis for these diseases. The review discusses new approaches to IIRD pharmacotherapy associated with the inhibition of tumor necrosis factor-α, interleukin-6 (IL-6), IL-1β, IL-17, IL-23, and the prospects for using Janus kinase inhibitors, depending on the prevailing pat
Ключевые слова:
Autoimmunity; Autoinflammation; Janus kinase inhibitors; Monoclonal antibodies
autoimmune disease; autoimmunity; human; rheumatic disease; rheumatoid arthritis; Sjoegren syndrome; systemic lupus erythematosus; Arthritis, Rheumatoid; Autoimmune Diseases; Autoimmunity; Humans; Lupus Erythematosus, Systemic; Rheumatic Diseases; Sjogren's Syndrome
Язык текста: Русский
ISSN: 2309-5342
Насонов Е. Л.
Nasonov E. L.
New directions of pharmacotherapy of immune-inflammatory rheumatic diseases
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 91, Вып. 8 С. 98-107
2019
Статья
Autoimmunity Autoinflammation Janus kinase inhibitors Monoclonal antibodies
autoimmune disease autoimmunity human rheumatic disease rheumatoid arthritis Sjoegren syndrome systemic lupus erythematosus Arthritis, Rheumatoid Autoimmune Diseases Autoimmunity Humans Lupus Erythematosus, Systemic Rheumatic Diseases Sjogren's Syndrome
Deciphering immunopathogenesis, expanding the scope of diagnostics and developing new methods for treating human autoimmune diseases are among the priority areas of XXI century medicine. Particularly widely autoimmune pathology is presented in immunoinflammatory rheumatic diseases (IIRD), such as rheumatoid arthritis, systemic lupus erythematosus, systemic scleroderma, systemic vasculitis associated with the synthesis of antineutrophilic cytoplasmic antibodies, Sjogren's syndrome, idiopathic inflammatory myopathies and other other types of others. Deciphering the pathogenesis mechanisms of IIRD created the prerequisites for improving pharmacotherapy, which in the future should lead to a dramatic improvement in the prognosis for these diseases. The review discusses new approaches to IIRD pharmacotherapy associated with the inhibition of tumor necrosis factor-α, interleukin-6 (IL-6), IL-1β, IL-17, IL-23, and the prospects for using Janus kinase inhibitors, depending on the prevailing pat